A novel series of 1-phenyl-3-aryl-4-R-pyrazoles (I) [aryl = Ph, 4-ClC6H4, 4-BrC6H4, 4-MeC6H4; R = (E)-CH:CHCO(CH2)2CO2H, CONH(o-C6H4)CONH2, CO2(o-C6H4)CONH2, CO2(p-C6H4)NHAc], analogs to lonazolac, was designed, synthesized, and evaluated for their anti-inflammatory as well as analgesic activities.To target preferential cyclooxygenase-2 (COX-2) inhibitors, the design of these compounds was based upon two different mol. modeling studies.The first study included fit-comparison study of conformational models of compounds I with a novel validated COX-2 inhibitors hypothesis generated from the corresponding leads using Hip-Hop CATALYST software.The second study included docking study of the designed compounds I with binding site of COX-1 and COX-2 enzymes using internal coordinate mechanics (ICM)-Pro software.The reported Akaho method was then used to predict the COX-2 selectivity of the designed compoundsI [aryl = Ph; R = (E)-CH:CHCO(CH2)2CO2H, CONH(o-C6H4)CONH2] and I [aryl = 4-ClC6H4; R = CO2(p-C6H4)NHAc] showed high activity in comparison with indomethacin, consistent with virtual mol. modeling studies.